Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Regulation FD disclosure furnished, not filed under Exchange Act Section 18.
Viridian Therapeutics, Inc.\DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Regulation FD disclosure furnished, not filed under Exchange Act Section 18
- Disclosure excluded from automatic incorporation into other SEC filings
- No substantive business, financial, or clinical information included in the provided text
Item 8.01 · Other Events
- FDA approval of Lumvoa (veligrotug-vvze) for TED regardless of activity or duration
- First TED treatment labeled with data covering both active and chronic disease
- Immediate commercial launch planned, creating potential near-term revenue opportunity
- Launch execution, adoption, reimbursement, and disclosed SEC risk factors remain key investor variables
Item EX-99.1 · Exhibit EX-99.1
- FDA approval makes Lumvoa Viridian’s first commercial product, enabling immediate U.S. launch for TED regardless of disease activity or duration
- Label covers both active and chronic TED, expanding the addressable treatment population versus activity-limited therapies
- Five intravenous infusions over 12 weeks, with proptosis reductions observed as early as three weeks
- Safety monitoring burden includes infusion reactions in approximately 9% of patients and hyperglycemia in 12%
- Elegrobart remains on track for BLA submission in Q1 2027, supporting a future subcutaneous TED option
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viridian Therapeutics, Inc.\DE 8-K filings
Get the next VRDN 8-K as it lands
Follow VRDN for push alerts, or ask the research agent what this filing means.